NASDAQ:ELDN Eledon Pharmaceuticals Q4 2025 Earnings Report $2.67 -0.04 (-1.48%) Closing price 04:00 PM EasternExtended Trading$2.69 +0.02 (+0.75%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eledon Pharmaceuticals EPS ResultsActual EPS-$0.10Consensus EPS -$0.20Beat/MissBeat by +$0.10One Year Ago EPSN/AEledon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEledon Pharmaceuticals Announcement DetailsQuarterQ4 2025Date3/19/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEledon Pharmaceuticals' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Eledon Pharmaceuticals Earnings HeadlinesEledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation SocietySeptember 9, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), AbbVie (ABBV)September 5, 2026 | theglobeandmail.comYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type of finance to build lasting wealth. Legendary investor Joel Greenblatt calls it 'the closest thing to a perpetual motion machine you will ever see.' One investor famously turned 50000 dollars into 900 million using this approach. Porter Stansberry breaks down its origins and mechanics in a new free documentary.September 16 at 1:00 AM | Porter & Company (Ad)Eledon Pharmaceuticals Submits IND Application to US FDA for TegoprubartSeptember 4, 2026 | finance.yahoo.comEledon Advances Tegoprubart In Islet Cell And Kidney Transplant ProgramsSeptember 3, 2026 | rttnews.comEledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 ...September 3, 2026 | markets.businessinsider.comSee More Eledon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email. Email Address About Eledon PharmaceuticalsEledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biotechnology company focused on developing therapies that modulate the immune system to address organ and cell transplantation, autoimmune disease, and other immune-mediated conditions. The company’s approach is designed to promote immune tolerance while reducing the need for conventional immunosuppressive treatments. Eledon’s lead product candidate is tegoprubart, an investigational monoclonal antibody that targets the CD40 ligand (CD40L) pathway. By blocking this pathway, tegoprubart is intended to help control immune responses involved in transplant rejection and autoimmune disease. The candidate has been evaluated in clinical development programs involving kidney transplantation and other potential transplant applications. Based in the United States, Eledon conducts research and clinical development activities through collaborations with medical centers and other organizations. The company’s programs remain investigational, and its therapies have not been established as approved treatments unless specifically authorized by regulatory agencies.View Eledon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big3 Luxury Consumer Brands to Watch in a Beaten-Down SectorJackson’s Record Quarter Powers the Bull CaseMarex Stock Doubles on Record Profits, But Can the Rally Continue?The Ultimate Cyber Shield: CrowdStrike Rises Past $2352 "Cheap for a Reason" Airline Stocks That May Be Worth the RiskMarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
